Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 2, 2017, Pages 206-214

  Nakajo, Masatoyo ^a   Jinguji, Megumi ^a   Nakabeppu, Yoshiaki ^a   Nakajo, Masayuki ^b   Higashi, Ryutarou ^a   Fukukura, Yoshihiko ^a   Sasaki, Ken ^a   Uchikado, Yasuto ^a   Natsugoe, Shoji ^a   Yoshiura, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Nanpuh Hospital   (Japan)

Author keywords

18F FDG PET CT; Esophageal cancer; MTV; Texture analysis; TLG

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS CANCER; FEMALE; GLYCOLYSIS; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CODING; PREDICTIVE VALUE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ALGORITHM; AUTOMATED PATTERN RECOGNITION; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; IMAGE ENHANCEMENT; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATTERN RECOGNITION, AUTOMATED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84986309694     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3506-2     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statics. CA Cancer J Clin. 2011;61:69–90.
2. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 2009;3:153–61.
3. Kato H, Fukuchi M, Manda R, Faried A, Takita J, Nakajima M, et al. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas. Anticancer Res. 2004;24:4091–6.
4. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, et al. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012;82:108–13.
5. Morita M, Kumashiro R, Hisamatsu Y, Nakanishi R, Egashira A, Saeki H, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol. 2011;46:1284–91.
6. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.
7. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.
8. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–22.
9. Kato H, Nakajima M. The efficacy of FDG-PET for the management of esophageal cancer: review article. Ann Thorac Cardiovasc Surg. 2012;18:412–9.
10. 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1595–606.
11. El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn. 2009;42:1162–71.
12. Cook GJ, O’Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, et al. Non-small cell lung cancer treated with erlotinib: heterogeneity of 18F-FDG uptake at PET-association with treatment response and prognosis. Radiology. 2015;276:883–93.
13. 18F-FDG PET/CT. Ann Nucl Med. 2016;30:309–19.
14. 18F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2016;43:1461–8.
15. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545–53.
16. van Baardwijk A, Bosmans G, van Suylen RJ, van Kroonenburgh M, Hochstenbag M, Geskes G, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87:55–8.
17. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–47.
18. Asselin MC, O’Connor JP, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer. 2012;48:447–55.
19. Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, et al. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med. 2013;54:1703–9.
20. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26.
21. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.
22. 18F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:1375–82.
23. 18F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1662–71.
24. Yip SS, Coroller TP, Sanford NN, Huynh E, Mamon H, Aerts HJ, et al. Use of registration-based contour propagation in texture analysis for esophageal cancer pathologic response prediction. Phys Med Biol. 2016;61:906–22.
25. 18F-FDG-PET scans of oesophageal cancer. Eur Radiol. 2015;25:2805–12.
26. Dong X, Xing L, Wu P, Fu Z, Wan H, Li D, et al. Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage. Nucl Med Commun. 2013;34:40–6.
27. Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44.
28. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721–4.
29. Galavis PE, Hollensen C, Jallow N, Paliwal B, Jeraj R. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. Acta Oncol. 2010;49:1012–6.
30. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med. 2012;53:693–700.
31. Gebejes A, Huertas R. Texture characterization based on grey-level Co-occurrence matrix. Proc ICTIC (Proc Conf Inf Manag Sci). 2013;2:375–8.
32. Cheng NM, Fang YH, Lee LY, Chang JT, Tsan DL, Ng SH, et al. Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2015;42:419–28.
33. Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.
34. Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med. 2014;55:37–42.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
36. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2- deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4:301–10.
37. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278–86.
38. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.